Validation of cytoplasmic-to-nuclear ratio of survivin as an indicator of improved prognosis in breast cancer

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Rexhepaj, Elton ^a   Jirstrom, Karin ^b   O'Connor, Darran P ^a   O'Brien, Sallyann L ^a   Landberg, Goran ^b   Duffy, Michael J ^a,c   Brennan, Donal J ^a   Gallagher, William M ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b LUND UNIVERSITY   (Sweden)

^c ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; SURVIVIN; TAMOXIFEN; BIRC5 PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HER2 PROTEIN, HUMAN; KI 67 ANTIGEN; MICROTUBULE ASSOCIATED PROTEIN; PROGESTERONE RECEPTOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; AUTOMATION; BREAST CANCER; BREAST CANCER SPECIFIC SURVIVAL; CANCER GRADING; CANCER SURVIVAL; CAUSE SPECIFIC SURVIVAL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASMIC TO NUCLEAR RATIO; DECISION TREE; DIGITAL IMAGING; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROCESS OPTIMIZATION; PROGNOSIS; QUANTITATIVE STUDY; STROMA; TISSUE MICROARRAY; ALGORITHM; AUTOMATED PATTERN RECOGNITION; BREAST TUMOR; CELL NUCLEUS; CHEMISTRY; CHI SQUARE DISTRIBUTION; COMPUTER ASSISTED DIAGNOSIS; CYTOPLASM; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; REPRODUCIBILITY; RISK ASSESSMENT; RISK FACTOR; SWEDEN; TIME; TREATMENT OUTCOME; VALIDATION STUDY;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; BREAST NEOPLASMS; CELL NUCLEUS; CHI-SQUARE DISTRIBUTION; CYTOPLASM; DECISION TREES; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; PATTERN RECOGNITION, AUTOMATED; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; SWEDEN; TAMOXIFEN; TIME FACTORS; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 78549255596     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-639     Document Type: Article

References (31)

1. Brennan DJ, O'Connor DP, Rexhepaj E, Ponten F, Gallagher WM. Antibody-based proteomics: fast-tracking molecular diagnostics in oncology. Nat Rev Cancer 10(9):605-617. 10.1038/nrc2902, 20720569.
2. Duffy MJ, O'Donovan N, Brennan DJ, Gallagher WM, Ryan BM. Survivin: A promising tumor biomarker. Cancer Lett 2007, 249(1):49-60. 10.1016/j.canlet.2006.12.020, 17275177.
3. Velculescu VE, Madden SL, Zhang L, Lash AE, Yu J, Rago C, Lal A, Wang CJ, Beaudry GA, Ciriello KM, et al. Analysis of human transcriptomes. Nat Genet 1999, 23(4):387-388. 10.1038/70487, 10581018.
4. Caldas H, Jiang Y, Holloway MP, Fangusaro J, Mahotka C, Conway EM, Altura RA. Survivin splice variants regulate the balance between proliferation and cell death. Oncogene 2005, 24(12):1994-2007. 10.1038/sj.onc.1208350, 15688031.
5. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997, 3(8):917-921. 10.1038/nm0897-917, 9256286.
6. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004, 351(27):2817-2826. 10.1056/NEJMoa041588, 15591335.
7. Chu JS, Shew JY, Huang CS. Immunohistochemical analysis of survivin expression in primary breast cancers. J Formos Med Assoc 2004, 103(12):925-931.
8. O'Driscoll L, Linehan R, S MK, Cronin D, Purcell R, Glynn S, E WM, A DH, N JOH, Parkinson M, et al. Lack of prognostic significance of survivin, survivin-deltaEx3, survivin-2B, galectin-3, bag-1, bax-alpha and MRP-1 mRNAs in breast cancer. Cancer Lett 2003, 201(2):225-236. 10.1016/S0304-3835(03)00518-4, 14607338.
9. Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M, Tanigawa N. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 2000, 6(1):127-134.
10. Kennedy SM, O'Driscoll L, Purcell R, Fitz-Simons N, McDermott EW, Hill AD, O'Higgins NJ, Parkinson M, Linehan R, Clynes M. Prognostic importance of survivin in breast cancer. Br J Cancer 2003, 88(7):1077-1083. 10.1038/sj.bjc.6600776, 2376388, 12671708.
11. Ryan BM, Konecny GE, Kahlert S, Wang HJ, Untch M, Meng G, Pegram MD, Podratz KC, Crown J, Slamon DJ, et al. Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. Ann Oncol 2006, 17(4):597-604. 10.1093/annonc/mdj121, 16403812.
12. Span PN, Sweep FC, Wiegerinck ET, Tjan-Heijnen VC, Manders P, Beex LV, de Kok JB. Survivin is an independent prognostic marker for risk stratification of breast cancer patients. Clin Chem 2004, 50(11):1986-1993. 10.1373/clinchem.2004.039149, 15364883.
13. Hinnis AR, Luckett JC, Walker RA. Survivin is an independent predictor of short-term survival in poor prognostic breast cancer patients. Br J Cancer 2007, 96(4):639-645. 10.1038/sj.bjc.6603616, 2360044, 17285125.
14. Brennan DJ, Kelly C, Rexhepaj E, Dervan PA, Duffy MJ, Gallagher WM. Contribution of DNA and Tissue Microarray Technology to the Identification and Validation of Biomarkers and Personalised Medicine in Breast Cancer. Cancer Genomics and Proteomics 2007, 4(2):3-16.
15. Brennan DJ, Rexhepaj E, O' Brien SL, Mc Sherry E, O'Connor DP, Fagan A, Culhane AC, Higgins DG, Jirstrom K, Millikan RC, et al. Altered cytoplasmic-nuclear ratio of survivin is a prognostic indicator in breast cancer. Clin Cancer Res 2008, 14(9):2681-2689. 10.1158/1078-0432.CCR-07-1760, 18451232.
16. Helczynska K, Larsson AM, Holmquist Mengelbier L, Bridges E, Fredlund E, Borgquist S, Landberg G, Pahlman S, Jirstrom K. Hypoxia-inducible factor-2alpha correlates to distant recurrence and poor outcome in invasive breast cancer. Cancer Res 2008, 68(22):9212-9220. 10.1158/0008-5472.CAN-08-1135, 19010893.
17. Rexhepaj E, Brennan DJ, Holloway P, Kay EW, McCann AH, Landberg G, Duffy MJ, Jirstrom K, Gallagher WM. Novel image analysis approach for quantifying expression of nuclear proteins assessed by immunohistochemistry: application to measurement of oestrogen and progesterone receptor levels in breast cancer. Breast Cancer Res 2008, 10(5):R89. 10.1186/bcr2187, 18947395.
18. O'Brien S, Fagan A, Fox E, Millikan R, Culhane A, Brennan D, McCann A, Hegarty S, Moyna S, Duffy M, et al. CENP-F expression is associated with poor prognosis and chromosomal instability in patients with primary breast cancer. Int J Cancer 2007, 120(7):1434-1443. 10.1002/ijc.22413, 17205517.
19. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch M, Sauter G, Kallioniemi O. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998, 4(7):844-847. 10.1038/nm0798-844, 9662379.
20. Rexhepaj E, Brennan DJ, Holloway P, Kay E, McCann AH, Landberg G, Duffy MJ, Jirstrom K, Gallagher WM. Novel image analysis approach for quantifying expression of nuclear proteins assessed by immunohistochemistry: application to measurement of estrogen and progesterone receptor levels in breast cancer. Breast Cancer Res 2008, 10(5):R89. 10.1186/bcr2187, 2614526, 18947395.
21. Brennan DJ, O'Brien SL, Fagan A, Culhane AC, Higgins DG, Duffy MJ, Gallagher WM. Application of DNA microarray technology in determining breast cancer prognosis and therapeutic response. Expert Opin Biol Ther 2005, 5(8):1069-1083. 10.1517/14712598.5.8.1069, 16050784.
22. Sawyers CL. The cancer biomarker problem. Nature 2008, 452(7187):548-552. 10.1038/nature06913, 18385728.
23. Fortugno P, Wall NR, Giodini A, O'Connor DS, Plescia J, Padgett KM, Tognin S, Marchisio PC, Altieri DC. Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function. J Cell Sci 2002, 115(Pt 3):575-585.
24. Knauer SK, Kramer OH, Knosel T, Engels K, Rodel F, Kovacs AF, Dietmaier W, Klein-Hitpass L, Habtemichael N, Schweitzer A, et al. Nuclear export is essential for the tumor-promoting activity of survivin. Faseb J 2007, 21(1):207-216. 10.1096/fj.06-5741com, 17099069.
25. Knauer SK, Mann W, Stauber RH. Survivin's dual role: an export's view. Cell Cycle 2007, 6(5):518-521.
26. Knauer SK, Bier C, Habtemichael N, Stauber RH. The Survivin-Crm1 interaction is essential for chromosomal passenger complex localization and function. EMBO Rep 2006, 7(12):1259-1265. 10.1038/sj.embor.7400824, 1794705, 17099693.
27. Colnaghi R, Connell CM, Barrett RM, Wheatley SP. Separating the anti-apoptotic and mitotic roles of survivin. J Biol Chem 2006, 281(44):33450-33456. 10.1074/jbc.C600164200, 16950794.
28. Span PN, Tjan-Heijnen VC, Manders P, van Tienoven D, Lehr J, Sweep FC. High survivin predicts a poor response to endocrine therapy, but a good response to chemotherapy in advanced breast cancer. Breast Cancer Res Treat 2006, 98(2):223-230. 10.1007/s10549-005-9153-0, 16541327.
29. Guo R, Huang Z, Shu Y, Jin S, Ge H. Tamoxifen inhibits proliferation and induces apoptosis in human hepatocellular carcinoma cell line HepG2 via down-regulation of survivin expression. Biomed Pharmacother 2009, 63(5):375-379. 10.1016/j.biopha.2008.09.010, 18993026.
30. Moriai R, Tsuji N, Moriai M, Kobayashi D, Watanabe N. Survivin plays as a resistant factor against tamoxifen-induced apoptosis in human breast cancer cells. Breast Cancer Res Treat 2009, 117(2):261-271. 10.1007/s10549-008-0164-5, 18815881.
31. Ryan BM, O'Donovan N, Duffy MJ. Survivin: A new target for anti-cancer therapy. Cancer Treat Rev 2009, 35(7):553-562. 10.1016/j.ctrv.2009.05.003, 19559538.